Patient Oriented Research in Pediatric Kidney Disease

描述（由申请人提供）：Susan Furth，医学博士，博士，儿科和流行病学教授，申请更新患者导向研究（K24）的中期职业奖。Furth博士在指导和成就方面有着杰出的记录。在该奖项的前4年里，Furth博士成功地指导了医学生、研究员和初级教师；其中6人获得NIH K23， KL2或K08职业发展奖，4人获得基金会或试点资助奖，均在学术界，政府或基金会进行研究。她继续工作并领导NIH/NIDDK的儿童慢性肾脏疾病队列（CKiD）研究，这是一项自2003年以来在美国和加拿大资助的586人CKD儿童队列研究。在此次续期申请中，Dr. Furth将继续指导博士后实习生和初级临床研究员，其中大部分还将接受宾夕法尼亚大学临床流行病学硕士项目的正式研究培训。Furth博士预计每年将成为2至3名博士后的主要教师导师，并为在CKiD进行辅助研究的初级教师提供指导。她以患者为导向的研究活动将继续解决CKD的问题，重点关注个体依赖透析或移植之前的疾病时期。CKiD已经达到了最初的招生目标，现在正在重新开放招生，并计划在2013年进行为期5年的续签申请。在这次K24更新中，Furth博士将通过CKiD和她在系里fr研究中的角色为她的学员提供研究机会，系里fr研究是CKiD的一项资助的辅助R01，其中包括在CKiD研究中对1482名CKD儿童进行基因分型，以及在欧洲ESCAPE和4C研究中。CKiD和配套的谱系fr研究为研究CKD病因、进展和相关合并症的遗传因素提供了一个理想的平台。本K24应用的其他研究目的是解决CKD中贫血和治疗抵抗这一重大问题的遗传贡献。研究基因对贫血易感性和治疗耐药性的影响可能会产生创新的治疗靶点。横断面和纵向分析将扩大我们对CKD中贫血和治疗抵抗的遗传贡献的理解。结合现有资助研究（包括CKiD和PediGFR）的数据作为指导平台的方法将提高父母研究的生产力，并推动初级研究人员的职业生涯成为下一代肾脏疾病研究的领导者。

DESCRIPTION (provided by applicant): Susan Furth, M.D., Ph.D. is a Professor of Pediatrics and Epidemiology applying to renew a Mid-career Award in Patient Oriented Research (K24). Dr. Furth has an outstanding record of mentorship and accomplishment. During the first 4 years of this award, Dr. Furth successfully mentored medical students, fellows and junior faculty; 6 of whom have received NIH K23, KL2 or K08 career development awards, and 4 foundation or pilot grant awards, all are pursuing research in academia, government or foundations. She continues to work with and lead the NIH/NIDDK's Chronic Kidney Disease in Children Cohort (CKiD) Study, a 586-person cohort study of children with CKD in the US and Canada funded since 2003. For this renewal application, Dr. Furth will continue her mentoring activities for both post-doctoral trainees and junior clinician researchers, the majority also receive formal research training in the Masters of Science Program in Clinical Epidemiology at the University of Pennsylvania.. Dr. Furth anticipates being the primary faculty mentor for 2 to 3 post-doctoral fellow mentees per year, and providing mentorship for junior faculty pursuing ancillary studies in CKiD. Her patient oriented research activities will continue to address problems in CKD, focusing on the period of disease before individuals become dependent on dialysis or transplantation. CKiD has met its initial enrollment goals and is now re-opening enrollment, and planning for a 5 year renewal application in 2013. In this K24 renewal, Dr. Furth will extend the research opportunities for her mentees through CKiD and her role on the PediGFR study, a funded ancillary R01 to CKiD which will include genotyping of a cohort of 1482 children with CKD in the CKiD study, as well as in the European ESCAPE and 4C studies. CKiD, and the ancillary PediGFR study, provide an ideal platform on which to conduct the study of genetic contributions to CKD causes, progression and associated comorbidities. The additional research aims of this K24 application address the genetic contributions to the significant problem of anemia and treatment resistance in CKD. Investigating genetic contributions to anemia susceptibility and treatment resistance may yield innovative therapeutic targets. Cross- sectional and longitudinal analyses will expand our understanding of the genetic contributions to anemia and treatment resistance in CKD. The approach of combining data from existing funded studies including CKiD and PediGFR as a platform for mentorship will increase the productivity of the parent studies and propel the careers of junior investigators to become the next generation of leaders in kidney disease research.